Overview of Procol

Property	Description
Active Ingredient	Probucol
Form	Oral Tablet
Pharmacological Class	Antihyperlipidemic Agent
General Purpose	Managing High Cholesterol
Origin	Synthetic, Bisphenol Derivative

What is Procol and What Class of Medicine Does It Belong To?

Procol is a prescription-only, single-ingredient medication classified as an Antihyperlipidemic Agent, with the general purpose of regulating and managing high blood cholesterol levels. The medicine contains the active substance Probucol, which places it within a distinct pharmacological category. This medication is confirmed to function as a hypocholesterolemic drug that modifies the body's lipid profile. Probucol is a cholesterol-lowering agent primarily used to decrease serum cholesterol and low-density lipoprotein levels. Procol's classification confirms its specialized role as a dedicated lipid-modifying agent intended to address elevated lipid levels in the circulation.

Procol's Composition, Origin, and Pharmaceutical Form

Procol is composed of the active chemical substance Probucol, a synthetic bisphenol derivative, and is supplied as an oral tablet along with various solid excipients that form the product’s structure. The drug is entirely synthetic in origin, developed as a chemical compound rather than being naturally derived. Its formulation as an oral tablet is the standardized method of delivery for the active component, ensuring the required systemic effects via the oral route of administration. This presentation is typical for medications intended for long-term lipid management.

General Therapeutic Role of This Lipid-Modifying Agent

The overall therapeutic role of Procol is to help maintain a healthier balance of cholesterol in the bloodstream, primarily through the accelerated clearance of circulating low-density lipoprotein cholesterol (LDL-C). Probucol is clinically recognized for its unique dual action, which involves enhancing the removal and excretion of LDL-C, often referred to as "bad cholesterol." This function, coupled with its established nature as a powerful antioxidant compound, contributes directly to the general benefit of managing and supporting a balanced lipid profile. Probucol possesses antioxidant properties that may benefit the overall process of lipid modification.

Regulatory References

MedlinePlus: Probucol

What side effects are possible with Procol?

Possible Side Effects and Safety Information for Procol

This section summarizes the safety profile of Procol, primarily based on data reviewed by governmental health authorities.

Common and Less Common Side Effects

The most frequently reported adverse reactions include gastrointestinal disturbances such as nausea, abdominal pain, diarrhea, and flatulence. Nervous system effects like headache and dizziness are also often noted. These reactions are typically mild to moderate in severity and may lessen over the course of treatment. Less common effects reported are rash, vomiting, and constipation.

Serious and Clinically Significant Adverse Reactions

Procol use is associated with a risk of serious, although rare, adverse events that require immediate medical attention. These include signs of severe hypersensitivity reactions (e.g., anaphylaxis, swelling of the face or throat) and organ system toxicity.

Hepatotoxicity: Liver function changes, including elevated liver enzymes, have been observed. Acute hepatic failure is a rare but serious documented risk. Regular monitoring of liver function tests may be recommended during therapy.
Blood Dyscrasias: Rare cases of blood disorders, such as agranulocytosis or other hematologic abnormalities, have been reported. Unexplained bruising, fever, or persistent sore throat should be reported.

Safety Considerations for Specific Populations

Hepatic Impairment: Caution is advised in patients with pre-existing liver conditions, and dose adjustment or enhanced monitoring may be necessary.
Hypersensitivity: The drug is contraindicated in patients with a known history of severe allergy to the active substance or chemically related compounds.
Pregnancy and Breastfeeding: Use during pregnancy or breastfeeding requires careful assessment of potential risks and benefits. Limited data suggest the drug may pass into breast milk.

It is important to discuss all pre-existing medical conditions and concerns with a healthcare provider to ensure safe use and appropriate monitoring of the drug.

Overdose and Emergency Response

The regulatory information concerning Procol overdose is centered on the potential for severe, documented cardiovascular toxicity. Overdose exposure is defined by the risk of cardiac instability, primarily manifesting as the Prolongation of the QT interval, which is a critical finding documented via electrocardiogram (ECG).

The most severe outcomes officially recognized in the regulatory prescribing information include Serious ventricular arrhythmias and the potential for life-threatening events such as cardiovascular-associated syncope. Due to the significant risk of cardiac complications, regulatory authorities explicitly mandate that individuals seek immediate medical attention and contact emergency services immediately upon any suspicion of overdose or accidental excessive exposure. Hospital monitoring is required in these situations.

Management procedures are defined by the need for continuous observation. Continuous Electrocardiogram (ECG) monitoring is required for assessing and managing cardiac rhythm until stability is confirmed. The official regulatory approach to treatment is limited to symptomatic and supportive treatment, as official labeling confirms that no specific antidote is documented for Probucol overdose. This procedural management is critical for addressing the documented, severe cardiac risks.

Therapeutic Uses of Procol

The therapeutic application of Procol (Probucol) is commonly used for the long-term management of specific, challenging lipid disorders and is applied in addressing associated vascular risk factors. It is generally used as a medicine to manage high levels of cholesterol in the blood. Its use is relevant in contexts involving heightened systemic burden related to lipid imbalances.

Procol is considered relevant for managing conditions such as primary hyperlipoproteinaemias (Type IIa and IIb), including familial hypercholesterolemia, and hyperlipidaemia secondary to chronic conditions. By assisting in the management of excess lipids and providing antioxidant properties, Procol contributes to easing the overall symptom load associated with cholesterol accumulation. This medicine is applied in clinical settings that involve chronic, severe lipid imbalances.

“The approach is generally intended to support the long-term management of the lipid profile, which may assist with general vascular health.”

Addressing Physical Manifestations and Vascular Health

The medication is relevant for easing symptom clusters that may become intense or disruptive, specifically by addressing the physical manifestations of cholesterol accumulation known as xanthomas. This use is generally applied in scenarios where additional management of discomfort is required, contributing to improved comfort during periods of heightened symptoms. Furthermore, its use may assist in supporting vascular health, and is relevant for managing conditions associated with high vascular risk.

Quick Fact: Support for Lipid-Related Manifestations Procol is applied in addressing physical symptoms associated with severe cholesterol buildup, such as the deposits known as xanthomas, supporting patients during difficult episodes and assisting with general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Procol?

Procol (Probucol) is an antihyperlipidemic agent for use in adult patients with specific lipid disorders, such as familial hypercholesterolemia. Eligibility for this medicine is strictly defined by regulatory documents based on pre-existing health conditions and population categories.

Absolute Contraindications (Must Not Use)

Procol is contraindicated and must not be used in individuals with a known hypersensitivity to Probucol or its components. It is also strictly prohibited in patients with certain heart-related conditions, including an unexplained prolonged QT interval (congenital or acquired), serious cardiac arrhythmias, or recent myocardial damage. Furthermore, patients with uncontrolled hypokalemia or hypomagnesemia must not use Procol.

Restrictions for Specific Populations

Population Group	Regulatory Status
Pregnancy	Contraindicated
Breastfeeding (Lactation)	Not recommended
Children/Adolescents (Under 18)	Not recommended; use is not established
Severe Hepatic Impairment	Not recommended
Severe Renal Impairment	Not recommended

Use of Procol is restricted when patients are concurrently taking other medicines known to prolong the QT interval. The official labeling establishes that use is primarily intended for the adult population, and insufficient data exists to support its safety and efficacy in the pediatric age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Procol (Probucol) has officially documented interaction patterns that primarily relate to cardiac rhythm and the medicine's absorption kinetics, as stated in regulatory prescribing information.

Contraindicated Combinations

Co-administration with other medicinal products known to prolong the QT interval is restricted or prohibited. This is due to an official additive pharmacodynamic interaction that increases the risk of serious ventricular arrhythmias. This restriction applies to drug classes such as certain Antiarrhythmics (Class I and III), Phenothiazines, and Tricyclic Antidepressants.

Pharmacokinetic and Pharmacodynamic Interactions

Exposure Reduction: Bile Acid Sequestrants (e.g., Cholestyramine) interfere with the absorption of Probucol, reducing its plasma exposure. Similarly, Probucol may reduce the blood concentration of Cyclosporin.
Potentiation: Probucol may potentiate the effects of oral antidiabetic medications and coumarin anticoagulants.

Administration Requirements and Restrictions

Interaction with Bile Acid Sequestrants necessitates a mandatory timing separation rule: Procol must be administered at least one hour before or four to six hours after the sequestrant to avoid absorption interference. Administration with food (meals) is also a required condition, as food increases the absorption of the medicine.

Population Note: Patients with Hepatic Function Impairment may exhibit higher blood levels of Probucol due to altered systemic clearance.

Mechanism of Action

Procol, identified here as Probucol, is a synthetic agent that modifies lipoprotein metabolism and possesses strong antioxidant properties. Its mechanism involves enhancing the catabolism and non-receptor-mediated clearance of low-density lipoprotein (LDL) particles, thereby reducing their circulating concentration. This process is independent of the classic LDL receptor pathway. Additionally, Probucol accumulates within the LDL particle itself, exerting a direct antioxidant effect that inhibits the oxidative modification of LDL cholesterol.

At the cellular level, the drug modulates reverse cholesterol transport by inhibiting the activity of the ATP-binding cassette transporter A1 (ABCA1), which typically facilitates cholesterol efflux from cells like macrophages into high-density lipoprotein (HDL) particles. Simultaneously, Procol increases the activity of cholesteryl ester transfer protein (CETP). These combined molecular actions result in a significant, though mechanistically complex, reduction in circulating HDL cholesterol concentration, alongside the reduction in LDL. The overall systemic physiological consequence is a modification of lipoprotein profile and reduced susceptibility of LDL to oxidation.

Dosage and Administration Information

Procol is an oral medication administered as a tablet. The standardized adult regimen specifies a total daily dose of 1,000 milligrams (1 gram), which is divided into two separate, equal administrations of 500 mg each.

Administration Timing and Schedule

A critical requirement for the use of this medicine is synchronization with food intake. Each 500 mg dose is taken with a meal, typically the morning and evening meals. This adherence to food timing is necessary to ensure optimal absorption of the active substance.

Therapy is generally structured for long-term, continuous administration as an adjunct to diet for the chronic management of specific lipid disorders, rather than for short-term use.

Special Procedural Conditions

The treatment regimen involves specific procedural conditions, including periodic clinical monitoring. This includes regular checks of serum lipid levels and Electrocardiograms (ECGs) throughout the administration period.

For scheduling deviations, if a dose is missed, standard procedure is to avoid taking a double dose. If the next administration time is imminent, the missed dose is skipped entirely to resume the regular schedule. Furthermore, usage constraints apply to specific populations; for instance, the medicine is not recommended for administration to children under two years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Procol (Probucol)

Evidence for Use in Managing Primary High Cholesterol (Hyperlipidaemia)

Research explored Procol's use in contexts related to high cholesterol levels, primarily using Randomized Controlled Trials (RCTs) and various long-term observational studies. These studies aimed to measure changes in key blood markers, particularly Low-Density Lipoprotein Cholesterol (LDL-C), often referred to as "bad cholesterol," and Total Cholesterol. Researchers also monitored the effect on High-Density Lipoprotein Cholesterol (HDL-C) and observed the size and presence of cholesterol deposits under the skin known as xanthomas.

Studies reported measurements of LDL-C and Total Cholesterol values during the study periods. The research also described the monitoring of physical signs of cholesterol accumulation, such as changes in the size of xanthomas, observed over several years in long-term cohorts. However, the data also show patterns where a decrease in HDL-C levels was simultaneously observed, which is a subject of documented scientific uncertainty.

Evidence for Use in High-Risk Vascular Conditions and Secondary Prevention

Research exploring Procol in patients with established vascular conditions used Randomized Controlled Trials (RCTs) and extended retrospective cohort studies that focused on individuals with existing Coronary Heart Disease (CHD) or other high-risk factors. These studies primarily monitored complex outcomes related to the frequency of major vascular events, such as stroke, heart attack, vascular death, and the need for revascularization procedures.

Research reports varying measurements of these complex endpoints across different trials. Some studies, particularly those conducted over many years in high-risk patient groups, described event patterns that varied numerically compared to the control group, but not all of these findings achieved definitive statistical certainty for the primary study goals. Because a large amount of the recent, dedicated evidence originates from high-risk patient cohorts predominantly in Asian populations, the generalizability of these particular findings to other groups remains insufficient.

What is Still Uncertain and Research Gaps

The evidence highlights areas where certainty remains low or where more research is needed:

Inconsistency in Clinical Outcomes: Some large RCTs did not achieve statistical certainty for their primary event endpoints, meaning findings were mixed or inconclusive for those specific measures.
Limited Long-Term Data: Data providing definitive information on long-term effects across all specific subgroups and clinical outcomes remain insufficient.
Observed Measurements of HDL-C: The documented pattern of simultaneous reduction in both LDL-C and HDL-C cholesterol levels is a documented finding, and the full meaning of the findings is a subject of ongoing research.

Key Studies & References

MedlinePlus Drug Information: Probucol

Frequently Asked Questions (FAQ)

Common questions about Procol (FAQ)

Q: Does Procol interact with common cold or allergy medicines?

Official documentation states that the medicine restricts co-administration with other medicinal products known to prolong the QT interval. This refers to drugs that can affect the electrical rhythm of the heart. The official label specifically names certain antiarrhythmics, phenothiazines, and tricyclic antidepressants, but does not categorize the entire broad class of common cold or allergy medicines.

Q: Is Procol the same type of medicine as [similar drug name]?

Procol is officially classified as an Antihyperlipidemic Agent, which means it is a drug used to help manage high lipid (fat) levels in the blood. The medicine contains the active substance Probucol, which places it within a distinct pharmacological category.

Q: Can Procol be taken with blood pressure medicine?

Official prescribing information restricts co-administration with medicines known to prolong the QT interval due to the risk of serious heart rhythm issues. While this restriction applies to certain antiarrhythmics (a type of heart medicine), the official label does not categorize the entire class of blood pressure medicines.

Q: What kind of studies were done to get Procol approved?

Research that supported the medicine's use included controlled clinical studies, such as Randomized Controlled Trials (RCTs), as well as various long-term observational studies. These studies were designed to measure changes in blood lipid markers and monitor complex vascular outcomes.

Q: What are the main findings from the pivotal trials of Procol?

Studies examined measurements of Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol, and monitored changes in the physical signs of cholesterol deposits known as xanthomas. The studies also reported a simultaneous reduction in High-Density Lipoprotein Cholesterol (HDL-C) levels, a pattern that is subject to ongoing research.

Q: Can Procol affect lab test results, like blood work?

Official documentation states that the use of Procol requires the periodic monitoring of serum lipid levels (blood fats) and Electrocardiograms (ECGs). Rare but serious changes in liver enzymes (indicating liver function) and hematologic abnormalities (blood disorders) have also been reported in safety data.

Q: How quickly does Procol typically start to work?

Official pharmacokinetic data indicates that this medicine takes time to build up in the body. If Procol is taken daily, three to four months are typically required to reach the target steady-state concentrations described in clinical data.

Q: Why is Procol only available by prescription?

Procol is classified as a prescription-only medication because its usage requires strict adherence to specific dosing conditions. Furthermore, official requirements mandate periodic clinical monitoring, which includes regular checks of serum lipid levels and heart activity via Electrocardiograms (ECGs).

Q: Is Procol a common drug in [country/region]?

The official evidence base notes that a large amount of dedicated research originates from patient cohorts predominantly in Asian populations. The medicine has specifically been approved for use in countries like Japan and China for the management of hyperlipidemia.

Q: Has there been any research on Procol's use in combination with therapy?

The medicine is structured for use as an adjunct to diet for the chronic management of specific lipid disorders. This means it is intended to be used alongside dietary changes, rather than as a standalone treatment.

Q: Do you have to take Procol at a specific time of day?

A critical requirement for the proper use of the medicine is synchronization with food intake. Each dose must be taken with a meal, typically the morning and evening meals, as described in official product labels. Official prescribing information requires synchronization with food intake (with a meal).

Q: Are there any known severe side effects I should be aware of?

Official safety information documents serious, though rare, adverse reactions. These include signs of severe hypersensitivity reactions, changes in liver function known as hepatotoxicity, and rare cases of blood dyscrasias (severe blood disorders).

Q: Is it possible to be allergic to Procol?

Official documents specify that the medicine is contraindicated, meaning it must not be used, in individuals with a known history of severe allergy or hypersensitivity to the active substance or its components. This indicates that allergic reactions are possible.

Q: Is it normal to have [mild, non-serious side effect, e.g., dry mouth] when starting Procol?

The most frequently reported adverse reactions, such as mild gastrointestinal disturbances or headache, are typically mild to moderate in severity. According to safety data, these effects may lessen over the course of treatment as the body adjusts to the medicine.

Q: What is the half-life of Procol?

The half-life relates to how quickly the medicine is eliminated from the body. Clinical data indicates that the drug's long half-life means its elimination is a prolonged process, resulting in three to four months being required to reach a stable concentration in the body with daily dosing.

Q: Are there different brand names for the same medicine as Procol?

The active ingredient in Procol is Probucol. This substance has been marketed in the United States under the brand name Lorelco, which is an example of an alternative brand name for the same medicine.

Q: What's the difference between the various strengths of Procol tablets?

Official product information describes Procol as an oral tablet. The standardized adult regimen specifies a defined dose that is divided and taken with meals. The product information is based on this standard regimen.

Q: Do clinical trials for Procol include children or adolescents?

Official documents state that the safety and efficacy of Procol in the pediatric age group (under 18) have not been established. Its use is not recommended for this population, as stated in official product information.

Q: Are there any long-term side effects associated with Procol use?

The official evidence base highlights a documented research gap. Data providing definitive information on long-term effects across all specific patient subgroups and clinical outcomes remain insufficient.

Q: Does Procol work immediately or build up in the system?

The medicine builds up in the system over time. Official pharmacokinetic data indicates that it typically requires three to four months to reach the target steady-state concentration in the body.

How should Procol be stored and disposed of?

How to Store and Dispose of Procol

Official regulatory documents define strict requirements for storing and disposing of Procol (Probucol) to maintain its stability and ensure safety.

Required Storage Conditions

Requirement Category	Condition
Temperature	Store at controlled room temperature, typically below 30°C (86°F), and keep away from heat.
Protection	The tablets must be protected from light and moisture.
Container	Keep the medicine in its original, tightly closed container and do not freeze.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Any unused or expired Procol must be disposed of in accordance with local requirements for medicinal products. The medication must not be disposed of via wastewater (e.g., flushed down the toilet) or general household waste. Do not keep outdated medicine.

Procol